Status:
UNKNOWN
Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Type1 Diabetes Mellitus
Type2 Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus
Eligibility Criteria
Inclusion
- T1DM or T2DM
- Female subjects must be non-pregnant and non-lactating
Exclusion
- Pregnant or lactating women
- Participation in an investigational study within 30 days prior to dosing
Key Trial Info
Start Date :
July 28 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03332849
Start Date
July 28 2015
End Date
April 30 2018
Last Update
November 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanmi Investigative Site
Chula Vista, California, United States, 91911